ANS Genesis RC
This article was originally published in The Gray Sheet
Executive Summary
Premarket development of "smaller" and "more powerful" second-generation rechargeable implantable pulse generators has begun following Advanced Neuromodulation Systems' recent PMA supplement approval of first-generation rechargeable Genesis RC and RC Dual neurostim systems for pain, the firm says. ANS is "building inventory" for a test launch. The firm previously offered non-rechargeable versions. Boston Scientific unit Advanced Bionics' Precision became the first FDA-approved rechargeable spinal cord stimulator in April...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.